Glucose, a type of sugar, is the brain’s primary fuel source.
From studying brain scans, researchers have established that in Alzheimer’s disease, brain cells no longer use glucose normally even if there is enough glucose available in the body. This change in the brain’s ability to use glucose, known as glucose hypometabolism, most often occurs in the areas of the brain involved in memory and thinking.
Glucose hypometabolism may be one of the earliest brain changes that occurs in Alzheimer’s, beginning years, sometimes decades before any symptoms of the disease appear.
In the NOURISH AD study, doctors want to learn if increasing ketones in the body with an investigational new drug can help memory and thinking skills in people with Alzheimer’s disease.
Ketone bodies are the brain’s natural back-up fuel
Substances called ketone bodies can also fuel the brain’s activities. When availability of glucose is low in the body, such as during fasting, the liver naturally produces ketone bodies from fat stores as an alternative fuel source for the brain.
Ketone bodies can supply up to 60% of the brain’s energy needs. However, the body’s production of ketone bodies stops when normal eating resumes. The body cannot increase ketone body production without very strict diet changes that are difficult to manage and maintain long term, particularly for people with Alzheimer’s disease.
Investigational drug provides ketone bodies
In the NOURISH AD study, doctors want to learn if increasing ketones in the body with an investigational new drug can help memory and thinking skills in people with Alzheimer’s disease. Want to learn more about this clinical research study?
You can call direct at 1-866-503-6006 (in the U.S.)
Or, you can click on the image to get more information about this clinical trial.
The NOURISH AD Trial is now open and recruiting new patients. NOURISH AD is a clinical research study evaluating the safety and effectiveness of an investigational drug for mild to moderate Alzheimer’s disease.
If you are interested in finding out if your loved one qualifies to participate for this clinical trial call 866 503 6006, or visit www.AD-Trial.com today!
Study volunteers must meet the following criteria to enroll:
- Be between the ages of 66-90
- Have mild to moderate Alzheimer’s disease or memory loss
- Have a study partner who can attend study visits
- Other criteria apply
- All study-related medicines and consultations specific to the study will be free of charge and compensation for travel may be available
- Participants may continue on their current AD medications
- Health insurance is not required to participate in this study
- Participants may help to advance a potential new treatment for mild to moderate Alzheimer’s disease
- 5 study visits and 3 phone visits over approximately 7 months
- All eligible participants will receive either study drug or placebo for 26 weeks. The study is blinded, so neither you nor the study staff will know what the participant is taking.
- After completion of the 26-week blinded study, participants will have the opportunity to take part in an optional 26-week extension study where all participants receive study drug
- Participants may continue to see their regular doctor while participating in this study
You are reading original content the Alzheimer's Reading Room